Page 56 - Read Online

Page 18 of 19 Casadei et al. J Cancer Metastasis Treat 2022;8:21 https://dx.doi.org/10.20517/2394-4722.2022.05

63. Czuczman MS, Leonard JP, Jung S, et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB
50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
Ann Oncol 2012;23:2356-62. DOI PubMed PMC
64. Lansigan F, Barak I, Pitcher B, et al. The prognostic significance of PFS24 in follicular lymphoma following firstline
immunotherapy: A combined analysis of 3 CALGB trials. Cancer Med 2019;8:165-73. DOI PubMed PMC
65. Jurczak W, Zinzani PL, Gaidano G, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-
cell non-Hodgkin's lymphoma. Ann Oncol 2018;29:1266-72. DOI PubMed PMC
66. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma
treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007;109:1804-10. DOI PubMed
67. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and
rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res
2005;11:5984-92. DOI PubMed
68. Chong EA, Ahmadi T, Aqui NA, et al. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients
with Indolent B-cell and Mantle Cell Lymphomas. Clin Cancer Res 2015;21:1835-42. DOI PubMed
69. Leonard JP, Jung SH, Johnson J, et al. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients
With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). J Clin Oncol 2015;33:3635-40. DOI PubMed PMC
70. Leonard JP, Trneny M, Izutsu K, et al; AUGMENT Trial Investigators. AUGMENT: A Phase III Study of Lenalidomide Plus
Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 2019;37:1188-99. DOI
PubMed PMC
71. Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label,
single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21:1433-42. DOI PubMed PMC
72. Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med
2014;370:1008-18. DOI PubMed PMC
73. Salles G, Schuster SJ, de Vos S, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-
refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica 2017;102:e156-9. DOI PubMed PMC
74. Gopal AK, Kahl BS, Flowers CR, et al. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after
initial chemoimmunotherapy. Blood 2017;129:3037-9. DOI PubMed
75. Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood 2016;128:331-6. DOI PubMed PMC
76. Cuneo A, Barosi G, Danesi R, et al. Management of adverse events associated with idelalisib treatment in chronic lymphocytic
leukemia and follicular lymphoma: A multidisciplinary position paper. Hematol Oncol 2019;37:3-14. DOI PubMed PMC
77. Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent
Non-Hodgkin Lymphoma. J Clin Oncol 2019;37:912-22. DOI PubMed
78. Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent
Lymphoma. J Clin Oncol 2017;35:3898-905. DOI PubMed
79. Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory
Indolent Lymphoma. J Clin Oncol 2021;39:1609-18. DOI PubMed PMC
80. Forero-Torres A, Ramchandren R, Yacoub A, et al. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with
relapsed or refractory B-cell malignancies. Blood 2019;133:1742-52. DOI PubMed PMC
81. Proudman D, Nellesen D, Gupta D, Adib D, Yang J, Mamlouk K. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in
Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat
was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and
Umbralisib. Adv Ther 2022;39:1678-96. DOI PubMed PMC
82. Gopal AK, Schuster SJ, Fowler NH, et al. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma:
Results From the Open-Label, Multicenter, Phase II DAWN Study. J Clin Oncol 2018;36:2405-12. DOI PubMed
83. Bartlett NL, Costello BA, LaPlant BR, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2
consortium trial. Blood 2018;131:182-90. DOI PubMed PMC
84. Tam CS, Quach H, Nicol A, et al. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and
follicular lymphoma. Blood Adv 2020;4:4802-11. DOI PubMed PMC
85. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet
2021;397:892-901. DOI PubMed
86. . National Comprehensive Cancer Network (NCCN) guidelines. Version 5.2021, 09/22/21
87. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl
J Med 2018;378:1107-20. DOI PubMed
88. Eyre TA, Roeker LE, Fox CP, et al. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic
lymphocytic leukaemia. Br J Haematol 2020;188:918-23. DOI PubMed PMC
89. Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Engl J Med
2018;378:1211-23. DOI PubMed
90. Davids MS, Roberts AW, Kenkre VP, et al. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Treated with Venetoclax in a Phase I, First-in-Human Study. Clin Cancer Res 2021;27:4690-5. DOI PubMed